Latest Cryogenics News

Archer Materials has made significant strides in quantum computing and biochip development, enhancing qubit functionality and potassium ion testing accuracy. A new partnership with IMEC aims to accelerate biochip commercialization, supported by a robust $11.6 million cash position.

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

Cryosite Limited reported a 12% increase in revenue for FY25, driven by a 58% surge in its ultra-frozen and cryogenic segment, while deferring dividends to fund expansion plans.

Archer Materials has successfully demonstrated its tunnel magnetoresistance (TMR) sensors operating at cryogenic temperatures, marking a key advance for quantum computing and advanced sensing applications.

HyTerra Limited has reported unexpectedly high helium concentrations of up to 4.4% in its Blythe 13-20 well in Kansas, marking a significant extension of the helium play in Eastern Kansas. The company plans to convert the well into an appraisal site to further evaluate this promising discovery.

First Graphene Limited is progressing two major projects in hydrogen storage and aerospace 3D printing, backed by multi-million-dollar UK grants to commercialise graphene-enhanced technologies.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.